Literature DB >> 19269635

Thromboangiitis obliterans in the 21st century--a new face of disease.

Rafał Małecki1, Krystyna Zdrojowy, Rajmund Adamiec.   

Abstract

Thromboangiitis obliterans (TAO) is a relatively rare disease of peripheral blood vessels, affecting small and medium sized arteries and veins. Although the first description of the disease was given by Winiwarter almost 130 years ago, etiology of TAO remains not elucidated. Smoking is considered as a precipitating factor of the disease. We emphasised some particular features of the new face of TAO - significant decrease in incidences, increased disease prevalence among women and coexistence of other than smoking atherosclerotic risk factors (especially disturbances of glucose metabolism). Contemporary methods of treatment were also discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269635     DOI: 10.1016/j.atherosclerosis.2009.01.042

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  17 in total

1.  Overnight deprivation from smoking disrupts amygdala responses to fear.

Authors:  Oezguer A Onur; Alexandra Patin; Yoan Mihov; Boris Buecher; Birgit Stoffel-Wagner; Thomas E Schlaepfer; Henrik Walter; Wolfgang Maier; René Hurlemann
Journal:  Hum Brain Mapp       Date:  2011-05-26       Impact factor: 5.038

2.  Thromoboagiitis Obliterans (TAO).

Authors:  Ui-Jun Park; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

Review 3.  Peripheral Arterial Disease Genetics: Progress to Date and Challenges Ahead.

Authors:  Nathan Belkin; Scott M Damrauer
Journal:  Curr Cardiol Rep       Date:  2017-11-01       Impact factor: 2.931

Review 4.  Pharmacological treatment for Buerger's disease.

Authors:  Daniel G Cacione; Cristiane R Macedo; Jose C C Baptista-Silva
Journal:  Cochrane Database Syst Rev       Date:  2016-03-11

5.  The prolonged clotting time in two female patients with thromboangiitis obliterans.

Authors:  Yiping Dang; Yin Xia; Yiqing Li; DannyC W Yu
Journal:  BMJ Case Rep       Date:  2013-06-06

6.  The incidence, prevalence, and survival rate of thromboangiitis obliterans in Korea: a retrospective population-based study.

Authors:  Bareun Choi; Shin Yi Jang; Seong-Kyong Kim; Nari Kim; Kyeongsug Kim; Dong Kyu Kim
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

7.  Buerger's disease: a multidisciplinary diagnostic and therapeutic challenge.

Authors:  Nassim Parvizi; Joseph Shalhoub; Alun H Davies
Journal:  JRSM Short Rep       Date:  2010-06-30

8.  Pharmacological treatment for Buerger's disease.

Authors:  Daniel G Cacione; Cristiane R Macedo; Frederico do Carmo Novaes; Jose Cc Baptista-Silva
Journal:  Cochrane Database Syst Rev       Date:  2020-05-04

9.  Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case-control study.

Authors:  Annie M Bérard; Aurélie Bedel; Rémi Le Trequesser; Geneviève Freyburger; Alan Nurden; Sylvie Colomer; Viviane Guérin; Marie-Christine Vergnes; François Becker; Gabriel Camelot; Luc Bressolette; Philippe Lacroix; Jean-Pierre Cambou; Alessandra Bura-Rivière; Joseph Emmerich; Michel Darmon; Anne-Marie Deletraz; Samir Mesli; Brigitte Colombies; Virginie Vanbrugghe; Claude Conri; Joël Constans
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

10.  Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease).

Authors:  Daniel G Cacione; Frederico do Carmo Novaes; Daniel H Moreno
Journal:  Cochrane Database Syst Rev       Date:  2018-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.